Investing For Life Meeting Poor People S Needs For Access To Medicines Through Responsible Business Practices

According to the World Health Organization, one-third of the global population lacks access to essential medicines. Should pharmaceutical companies be ethically or legally responsible for providing affordable medicines for these people, even though they live outside of profitable markets? Can the private sector be held accountable for protecting human beings' right to health? This thought-provoking interdisciplinary collection grapples with corporate responsibility for the provision of medicines in low- and middle-income countries. The book begins with an examination of human rights, norms, and ethics in relation to the private sector, moving to consider the tensions between pharmaceutical companies' social and business duties. Broad examinations of global conditions are complemented by case studies illustrating different approaches for addressing corporate conduct. Access to Medicines as a Human Right identifies innovative solutions applicable in both global and domestic forums, making it a valuable resource for the vast field of scholars, legal practitioners, and policymakers who must confront this challenging issue.

Transnational corporations are one of the most important actors in the global economy, occupying a more powerful position than ever before. In their persistent battle to increase profits, they have increasingly turned to the developing world, a world that holds many attractions for them. But what is their impact on the poor? Now in its second edition, Big Business, Poor Peoples finds that these corporations are damaging the lives of millions of poor people in developing countries. Looking at every sector where transnational corporations are involved, this vital book is packed with detail on how the poor are affected. The book exposes how developing countries’ natural resources are being ceded to TNCs and how governments are unwilling or unable to control them. The author argues that TNCs, answerable to no one but their shareholders, have used their money, size and power to influence international negotiations and taken full advantage of the move towards privatization to influence government policies; sovereignty is passing into corporate hands, and the poor are paying the price. But people are fighting back: citizens, workers, and communities are exposing the corporations and looking for alternatives. The first edition of this path-breaking book put the issue of transnational corporations and the poor firmly on the agenda. This second edition contains significant new and updated material and is an essential read for anyone who wants to know more about the effects of corporate power on the poor.

Includes bibliographical references and index.

An innovative textbook setting out a systematic approach to business and human rights.

This book begins the discourse on post-trial access to drugs in developing countries. Underlying ethical issues in global health inequalities and global health research serve as the context of the debate. Due to rampant allegations of violations of rights of research participants, especially in developing countries, it discusses the regulatory infrastructure and ethical oversight of international clinical research, thus emphasizing the priority of safeguarding the rights of research participants and host populations as desiderata in conducting clinical trials in developing countries. This is the first book that analyzes the major obstacles of affordable access to drugs in developing countries – patent and non-patent factors and how they can be overcome through a middle ground approach and a new paradigm to establish global health justice which includes national and global health responsibilities. The book also deals extensively with all complex aspects of the discourse on affordable access to drugs in developing countries, including intellectual property law, international regulations, political and cultural systems, international trade agreements. Furthermore it contains a robust ethical debate and in-depth analysis. The book crafts a paradigm of global health justice involving a sliding scale of national and global responsibilities for the realization of the right to health in general and access to drugs in particular.

This second edition of A Companion to Bioethics, fully revised and updated to reflect the current issues and developments in the field, covers all the material that the reader needs to thoroughly grasp the ideas and debates involved in bioethics. Thematically organized around an unparalleled range of issues, including discussion of the moral status of embryos and fetuses, new genetics, life and death, resource allocation, organ donations, AIDS, human and animal experimentation, health care, and teaching Now includes new essays on currently controversial topics such as cloning and genetic enhancement Topics are clearly and compellingly presented by internationally renowned bioethicists A detailed index allows the reader to find terms and topics not listed in the titles of the essays themselves